genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Spero Therapeutics
Infectious Diseases
Antimicrobial Resistance: Multiple Threats, Multiple Responses
GEN Edge
StockWatch: After Bluebird’s Second Approval, Investors Are Looking for More
A-Lists
Top 10 Under 40 of 2019
Drug Discovery
Spero Wins Up to $54M Toward Development of Lead Antibiotic SPR994 for UTI
Drug Discovery
With Up-to-$6.8M Grant, Spero Therapeutics to Advance Lead Candidate
Drug Discovery
Spero Buys Antibacterial Candidates from Pro Bono Bio
Industry News
Spero Therapeutics Wins $1.65M DoD Award toward Potentiator Program
Drug Discovery
Biota Pharmaceuticals Sells Antibiotic Program to Spero Therapeutics
Drug Discovery
Startup Spero Makes Antibiotics Pact with Roche
Scroll Up
Scroll Up
